ALLK

Allakos Inc. [ALLK] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ALLK Stock Summary

Top 10 Correlated ETFs

ALLK


Top 10 Correlated Stocks

ALLK


In the News

01:11 28 Mar 2024 ALLK

Allakos (ALLK) Plummets 60% on Ending Development of Lead Drug

Allakos (ALLK) decides to stop developing its lead drug after top-line data from two mid-stage studies did not achieve their primary endpoints.

11:36 28 Mar 2024 ALLK

Why Is Allakos (ALLK) Stock Down 57% Today?

Allakos (NASDAQ: ALLK ) stock is taking a beating on Tuesday after the clinical stage biopharmaceutical company revealed results from its latest study. The bad news here comes from the company's Phase 2 and Phase 2b clinical trials of lirentelimab.

11:26 28 Mar 2024 ALLK

Is Allakos (ALLK) Stock Outpacing Its Medical Peers This Year?

Here is how Allakos Inc. (ALLK) and McKesson (MCK) have performed compared to their sector so far this year.

07:30 28 Mar 2024 ALLK

Allakos to stop further development of skin disease drug, plans job cuts

Allakos Inc said on Tuesday that it plans to discontinue the development of its experimental skin disease drug after it failed two mid-stage studies.

12:10 28 Mar 2024 ALLK

Why Shares of Allakos Are Up Wednesday

An analyst's recommendation may have helped boost Allakos stock. Allakos has two lead therapies to treat autoimmune skin disorders.

02:07 28 Mar 2024 ALLK

Scratching The Surface: Allakos' Novel Take On Urticaria

Allakos displays fiscal discipline with YoY reductions in R&D and G&A, suggesting resource reallocation to pivotal assets like lirentelimab. Lirentelimab's Phase 2a data is promising, particularly for omalizumab-refractory patients, but late-phase results are keys to the drug's validation. Investment Recommendation: Speculative "Buy" advised for bold investors. Initiate starter positions, closely monitor upcoming Phase 2b data and cash burn rate.

09:23 28 Mar 2024 ALLK

May MDA Breakout Stocks/ETFs Week 21 - 2023: High-Frequency Gainers To Give You An Edge

Two new Breakout Stocks for Week 21 with better than 10% short-term upside, ETF updates and a Dow 30 Pick. Average cumulative returns for 2023 are +74.8% YTD. Last week we had peak gains in ANNX +16%, EHTH +13.2%, FLNC +9%, ALLK +7.5%. The Active ETF portfolio continues with YTD gains at +10.6%.

05:00 28 Mar 2024 ALLK

Why Allakos Stock Skyrocketed Nearly 9% Higher Today

An analyst bumped his recommendation higher. This closely followed an encouraging quarterly earnings report/business update from the biotech.

04:05 28 Mar 2024 ALLK

Why Allakos Stock Was Heating Up Today

Allakos is barreling toward two mid-stage data readouts that could alter its long-term outlook. An analyst thinks these twin catalysts could cause the biotech's shares to more than quadruple in value.

01:33 28 Mar 2024 ALLK

Allakos Inc. (ALLK) Moves to Buy: Rationale Behind the Upgrade

Allakos Inc. (ALLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ALLK Financial details

Company Rating
Neutral
Market Cap
118.63M
Income
-183.06M
Revenue
0
Book val./share
1.93
Cash/share
1.95
Dividend
-
Dividend %
-
Employees
131
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-1.76
Forward P/E
-1.69
PEG
0.3
P/S
-
P/B
1.27
P/C
0.65
P/FCF
-2.02
Quick Ratio
8.27
Current Ratio
9.31
Debt / Equity
0.25
LT Debt / Equity
0.23
-
-
EPS (TTM)
-2.1
EPS next Y
-0.75
EPS next Q
-0.46
EPS this Y
-57.37%
EPS next Y
-64.29%
EPS next 5Y
-152.5%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
36.54%
-
-
-
-
SMA20
-
SMA50
-50%
SMA100
-50%
Inst Own
56.35%
Inst Trans
0.69%
ROA
-57%
ROE
-60%
ROC
-0.68%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
87.87M
Shs Float
71.88M
-
-
-
-
Target Price
110.5
52W Range
1.0-5.64
52W High
-74.7%
52W Low
+26.5%
RSI
45
Rel Volume
0.27
Avg Volume
1.58M
Volume
422.49K
Perf Week
-3.44%
Perf Month
-0.39%
Perf Quarter
-48.16%
Perf Half Y
-40.89%
-
-
-
-
Beta
0.818
-
-
Volatility
0.03%, 0.11%
Prev Close
-1.17%
Price
1.265
Change
-4.17%

ALLK Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-1.72-2.98-4.96-5.02-2.14
Operating cash flow per share
-1.39-2.3-3.86-4.42-1.34
Free cash flow per share
-1.41-2.31-4.48-4.56-1.35
Cash per share
10.9713.327.884.421.97
Book value per share
10.9713.228.284.911.94
Tangible book value per share
10.9713.228.284.911.94
Share holders equity per share
10.9713.228.284.911.94
Interest debt per share
0.330.870.960.830.48
Market cap
4.31B6.93B527.02M532.85M236.96M
Enterprise value
4.28B6.76B423.29M494.74M211.98M
P/E ratio
-55.49-46.94-1.97-1.68-1.28
Price to sales ratio
00000
POCF ratio
-68.39-60.82-2.54-1.9-2.03
PFCF ratio
-67.56-60.49-2.19-1.85-2.02
P/B Ratio
8.6910.591.181.721.4
PTB ratio
8.6910.591.181.721.4
EV to sales
00000
Enterprise value over EBITDA
-46.81-43.07-1.56-1.53-1.12
EV to operating cash flow
-67.92-59.38-2.04-1.77-1.82
EV to free cash flow
-67.1-59.05-1.76-1.72-1.81
Earnings yield
-0.02-0.02-0.51-0.6-0.78
Free cash flow yield
-0.01-0.02-0.46-0.54-0.49
Debt to equity
0.020.070.120.160.25
Debt to assets
0.020.060.10.130.17
Net debt to EBITDA
0.331.050.380.120.13
Current ratio
38.2729.8111.2210.284.92
Interest coverage
-14.7400-87.780
Income quality
0.740.740.770.880.63
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.010.010.160.030.01
Capex to revenue
00000
Capex to depreciation
-0.51-0.41-14.38-1.18-0.1
Stock based compensation to revenue
00000
Graham number
20.629.7930.423.539.68
ROIC
-0.16-0.2-0.49-0.79-0.79
Return on tangible assets
-0.15-0.21-0.5-0.82-0.76
Graham Net
10.5126.223.221.11
Working capital
486.81M646.82M411.33M278.81M143.31M
Tangible asset value
495.72M654.4M445.48M310.43M168.82M
Net current asset value
478.7M604.04M362.23M232.86M105.1M
Invested capital
0.020.070.120.160.25
Average receivables
00000
Average payables
4.03M9.96M13.83M9.26M3.3M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
1.44K2.18K1.02K176.81104.85
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0.250.170.362.063.48
Inventory turnover
00000
ROE
-0.16-0.23-0.6-1.02-1.1
Capex per share
-0.02-0.01-0.62-0.13-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.47-0.46-0.41-0.52-0.71
Operating cash flow per share
-0.55-0.35-0.38-0.34-0.28
Free cash flow per share
-0.55-0.35-0.38-0.34-0.28
Cash per share
3.282.942.552.231.95
Book value per share
3.643.272.942.541.93
Tangible book value per share
3.643.272.942.541.93
Share holders equity per share
3.643.272.942.541.93
Interest debt per share
0.610.470.490.480.47
Market cap
717.91M382.01M377.78M197.75M239.06M
Enterprise value
679.8M331.52M350.13M169M214.08M
P/E ratio
-4.51-2.4-2.69-1.08-0.96
Price to sales ratio
00000
POCF ratio
-15.34-12.67-11.59-6.71-9.85
PFCF ratio
-15.25-12.56-11.5-6.68-9.86
P/B Ratio
2.311.361.480.891.42
PTB ratio
2.311.361.480.891.42
EV to sales
00000
Enterprise value over EBITDA
-14.71-7.62-9.26-3.62-3.37
EV to operating cash flow
-14.53-11-10.74-5.73-8.82
EV to free cash flow
-14.44-10.9-10.66-5.71-8.83
Earnings yield
-0.06-0.1-0.09-0.23-0.26
Free cash flow yield
-0.07-0.08-0.09-0.15-0.1
Debt to equity
0.160.150.170.190.25
Debt to assets
0.130.120.130.150.17
Net debt to EBITDA
0.821.160.730.620.39
Current ratio
10.289.5810.279.314.92
Interest coverage
-16.6517.05000
Income quality
1.090.710.930.650.39
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.010.010.0100
Capex to revenue
00000
Capex to depreciation
-0.19-0.18-0.17-0.070.02
Stock based compensation to revenue
00000
Graham number
6.185.835.185.475.57
ROIC
-0.11-0.12-0.11-0.15-0.26
Return on tangible assets
-0.1-0.11-0.11-0.16-0.26
Graham Net
2.392.131.811.511.1
Working capital
278.81M253.33M227.08M194.83M143.31M
Tangible asset value
310.43M280.45M254.98M221.04M168.82M
Net current asset value
232.86M212.9M187.34M155.83M105.1M
Invested capital
0.160.150.170.190.25
Average receivables
00000
Average payables
4.72M6.97M6.7M2.61M1.34M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
222.33409.95211.753.16102.62
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0.40.220.431.690.88
Inventory turnover
00000
ROE
-0.13-0.14-0.14-0.21-0.37
Capex per share
00000

ALLK Frequently Asked Questions

What is Allakos Inc. stock symbol ?

Allakos Inc. is a US stock , located in Redwood city of Ca and trading under the symbol ALLK

Is Allakos Inc. buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $110.5. The lowest prediction is $3 and the highest is $218

What is ALLK stock prediction ?

With a median analyst target price of $3, 1 stock analysts have made 1 forecasts in last 90 days. $3 is the lowest and $3 is the greatest projection.

What is Allakos Inc. stock quote today ?

Allakos Inc. stock price is $1.265 today.

Is Allakos Inc. stock public?

Yes, Allakos Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap